Madrigal Pharmaceuticals price to sales ratio MDGL
Market value divided by revenue over the last twelve months, since 2012.
- Today, Nov 2, 2026
- 7.8×
- 2-year median
- 18.1×
- Against its 2-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 7.7× to 99.6×
- Peer median
- 6.5×
Madrigal Pharmaceuticals' price to sales ratio is 7.8× as of Nov 2, 2026.
That is below its 2-year median of 18.1×, lower than on 99% of days in the last 2 years.
Over that time it ranged from 7.7× in Oct 2026 to 99.6× in Nov 2024.
The median for 10 large drugmakers of a similar size is 6.5×.
Price to sales ratio over time
The dashed line is the 2-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.8× | 7.7× | 18.2× |
| 2025 | 18.4× | 14.9× | 96.2× |
| 2024 | 88.9× | 81.9× | 99.6× |
| 2023 | n/m a value too high to mean anything | ||
| 2022 | n/m a value too high to mean anything | ||
| 2021 | n/m a value too high to mean anything | ||
| 2020 | n/m a value too high to mean anything | ||
| 2019 | n/m a value too high to mean anything | ||
| 2018 | n/m a value too high to mean anything | ||
| 2017 | n/m a value too high to mean anything | ||
| 2016 | n/m a value too high to mean anything | ||
| 2015 | n/m a value too high to mean anything | ||
| 2014 | n/m a value too high to mean anything | ||
| 2013 | 170× | 150× | 199× |
| 2012 | 154× | 32.5× | 157× |
Against its peers
Companies in Drug Manufacturers - General nearest Madrigal Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| MDGLMadrigal Pharmaceuticals | 7.8× |
| TGTXTG Therapeutics | 11.5× |
| PTGXProtagonist Therapeutics | 32.0× |
| BMRNBiomarin Pharmaceutical | 3.3× |
| CORTCorcept Therapeutics | 10.5× |
| ALKSAlkermes plc. | 4.5× |
| JAZZJazz Pharmaceuticals | 3.0× |
| KNSAKiniksa Pharmaceuticals International | 8.4× |
| AMRXAmneal Pharmaceuticals | 2.1× |
| LGNDLigand Pharmaceuticals | 21.1× |
| INDVIndivior Pharmaceuticals | 3.1× |
| Peer median | 6.5× |
Where Madrigal Pharmaceuticals ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Madrigal Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.